-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sorrento Therapeutics (NASDAQ:SRNE) Shares Gap Up to $1.51
Sorrento Therapeutics (NASDAQ:SRNE) Shares Gap Up to $1.51
Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) shares gapped up before the market opened on Tuesday . The stock had previously closed at $1.51, but opened at $1.61. Sorrento Therapeutics shares last traded at $1.59, with a volume of 35,558 shares.
Sorrento Therapeutics Stock Performance
The business has a fifty day moving average of $2.25 and a 200-day moving average of $2.05. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.21 and a current ratio of 1.35.
Get Sorrento Therapeutics alerts:Insider Buying and Selling
In related news, insider Henry Ji acquired 22,222 shares of the company's stock in a transaction that occurred on Thursday, August 25th. The shares were acquired at an average price of $2.06 per share, with a total value of $45,777.32. Following the acquisition, the insider now owns 2,088,029 shares of the company's stock, valued at approximately $4,301,339.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.30% of the stock is currently owned by insiders.
Institutional Trading of Sorrento Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. B. Riley Wealth Management Inc. purchased a new stake in shares of Sorrento Therapeutics in the 2nd quarter valued at about $11,363,000. Verition Fund Management LLC purchased a new stake in shares of Sorrento Therapeutics in the 2nd quarter valued at about $44,000. Legal & General Group Plc raised its holdings in shares of Sorrento Therapeutics by 28.7% in the 2nd quarter. Legal & General Group Plc now owns 345,981 shares of the biopharmaceutical company's stock valued at $696,000 after acquiring an additional 77,177 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Sorrento Therapeutics by 23.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,939,979 shares of the biopharmaceutical company's stock valued at $3,900,000 after acquiring an additional 362,913 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Sorrento Therapeutics by 8.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 141,561 shares of the biopharmaceutical company's stock valued at $285,000 after acquiring an additional 10,846 shares in the last quarter. Hedge funds and other institutional investors own 33.61% of the company's stock.Sorrento Therapeutics Company Profile
(Get Rating)
Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
See Also
- Get a free copy of the StockNews.com research report on Sorrento Therapeutics (SRNE)
- Build A Better Tech Portfolio With Jabil Inc.
- Autodesk Is A Mature Company Still Acting Like A Growth Stock
- Is There Value In These Growth Stocks?
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
索伦托治疗公司(纳斯达克代码:SRNE-GET评级)的股票在周二开盘前大幅上涨。该股此前收盘报1.51美元,开盘报1.61美元。索伦托治疗公司的股票最新报1.59美元,成交量为35,558股。
索伦托治疗公司股票表现
该业务的50日移动均线切入位在2.25美元,200日移动均线切入位在2.05美元。该公司的负债权益比率为0.61,速动比率为1.21,流动比率为1.35。
到达索伦托治疗公司警报:内幕买卖
在相关新闻中,内部人士纪万昌在8月25日(星期四)的一笔交易中收购了该公司22,222股股票。这些股票是以每股2.06美元的平均价格收购的,总价值为45,777.32美元。收购完成后,这位内部人士现在拥有该公司2,088,029股股票,价值约4,301,339.74美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站。3.30%的股份目前由内部人士持有。
索伦托治疗公司的机构交易
几家机构投资者和对冲基金最近调整了对该公司的持股。B.莱利财富管理公司在第二季度购买了索伦托治疗公司的新股份,价值约11,363,000美元。Verition Fund Management LLC在第二季度购买了Sorrento治疗公司的新股份,价值约44,000美元。Legal&General Group Plc在第二季度将其在Sorrento Treeutics的股票持有量增加了28.7%。Legal&General Group Plc现在拥有这家生物制药公司345,981股股票,价值696,000美元,上个季度又收购了77,177股。高盛股份有限公司在第二季度增持了23.0%的索伦托治疗公司股票。高盛股份有限公司在上个季度增持了362,913股后,现在持有这家生物制药公司1,939,979股股票,价值3,900,000美元。最后,Price T Rowe Associates Inc.MD在第二季度将其持有的Sorrento Treateutics股票增加了8.3%。Price T Rowe Associates Inc.MD现在持有这家生物制药公司141,561股股票,价值28.5万美元,上个季度又收购了10,846股。对冲基金和其他机构投资者持有该公司33.61%的股份。索伦托治疗公司简介
(获取评级)
索伦托治疗公司是一家临床阶段和商业生物制药公司,开发癌症、自身免疫、炎症、病毒和神经退行性疾病的治疗方法。它通过两个部门运营,索伦托治疗公司和Scilex。该公司通过利用其专有的G-MAB抗体库和靶向递送方式提供癌症治疗,其中包括嵌合抗原受体T细胞疗法(CAR-T)、二聚体抗原受体T细胞疗法、抗体药物结合物以及双特异性抗体方法;以及Sofusa,一种将生物细胞直接输送到淋巴系统的药物递送技术。
另请参阅
- 免费获取StockNews.com关于索伦托治疗公司(SRNE)的研究报告
- 与捷普公司一起打造更好的技术产品组合。
- 欧特克是一家成熟的公司,仍是一只成长型股票
- 这些成长型股票有价值吗?
- MarketBeat Podcast,3只股票关注纽蒙特矿业、沃尔玛、AMC
- Mo Money:奥驰亚集团股价为何上涨
接受《索伦托治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对索伦托治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧